

Dr. William Shen is currently Director, Mergers & Acquisitions at Bristol-Myers Squibb.

Prior to joining BMS, Will was Head of Strategy & Business Development at JHL Biotech, a biosimilar company founded by KPCB and Sequoia Capital. Before JHL, Will was a Partner at venBio, a venture capital firm with a model that integrates strategic and financial investing. Prior to joining venBio, Will was an Associate at Johnson & Johnson Development Corporation (JJDC), the venture capital arm of J&J. Will started his career at Alexza Pharmaceuticals, an innovative inhalation drug delivery company. During his tenure at Alexza, he led pre-clinical and early clinical development of three lead CNS drug candidates.

Will received a PhD in Biophysics from Stanford University and a MBA from the Wharton School of the University of Pennsylvania with dual majors in Finance and Health Care Management.